Peptide Atlas · Other substance

Thymostimulin (TP-1)

In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change.

emerging

provisional
2 citations
0 discussions
0 followers
TP-1
calf thymus extract TP-1
thymostimulin

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Thymostimulin in severe atopic eczema: transient benefit (RCT, n=29) standing
- resolved
A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema.
Harper JI, Mason UA, White TR, Staughton RC, Hobbs JR
pmid 1835403
- preclinical
  Claim: Thymostimulin increased survival of tumour-bearing mice standing
- resolved
Effect of the thymic factor, thymostimulin (TP-1), on the survival rate of tumor-bearing mice.
Klein AS, Shoham J
pmid 7248976

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.